KRAS mutations can cause a sustained activation of the RAS–RAF–MAPK signalling pathway, promoting the proliferation of tumour cells and leading to an ineffective treatment with anti-EGFR monoclonal antibodies (6). The gene discussed is KRAS; the disease is neoplasm.